



## Exelixis to Present at the Stifel 2016 Healthcare Conference on November 15

November 7, 2016

-- Presentation to be webcast on [www.exelixis.com](http://www.exelixis.com) --

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 7, 2016-- Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide an overview of the company at Stifel's 2016 Healthcare Conference taking place November 15-16 in New York. The Exelixis presentation is scheduled for 11:45 AM EST/8:45 AM PST on Tuesday, November 15, 2016.

The presentation will be webcast live and may be accessed via the Event Calendar page under Investors & Media at [www.exelixis.com](http://www.exelixis.com). Please connect to the company's website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 14 days.

### About Exelixis

Exelixis, Inc. (Nasdaq: EXEL) is a biopharmaceutical company committed to the discovery, development and commercialization of new medicines with the potential to improve care and outcomes for people with cancer. Since its founding in 1994, three medicines discovered at Exelixis have progressed through clinical development to receive regulatory approval. Currently, Exelixis is focused on advancing cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL and VEGF receptors, which has shown clinical anti-tumor activity in more than 20 forms of cancer and is the subject of a broad clinical development program. Two separate formulations of cabozantinib have received regulatory approval to treat certain forms of kidney and thyroid cancer and are marketed for those purposes as CABOMETRYX™ tablets (U.S. and EU) and COMETRIQ® capsules (U.S. and EU), respectively. Another Exelixis-discovered compound, COTELLIC® (cobimetinib), a selective inhibitor of MEK, has been approved in major territories including the United States and European Union, and is being evaluated for further potential indications by Roche and Genentech (a member of the Roche Group) under a collaboration with Exelixis. For more information on Exelixis, please visit [www.exelixis.com](http://www.exelixis.com) or follow @ExelixisInc on Twitter.

*Exelixis, the Exelixis logo, COMETRIQ and COTELLIC are registered U.S. trademarks, and CABOMETRYX is a U.S. trademark.*



View source version on businesswire.com: <http://www.businesswire.com/news/home/20161107006342/en/>

Source: Exelixis, Inc.

Exelixis, Inc.  
Susan Hubbard, 650-837-8194  
Investor Relations and  
Public Affairs  
[shubbard@exelixis.com](mailto:shubbard@exelixis.com)  
or  
For Exelixis, Inc.  
Hal Mackins, 415-994-0040  
[hal@torchcomllc.com](mailto:hal@torchcomllc.com)